8-K: Aytu BioPharma Reports Q1 FY26 Results, EXXUA Launch On Track

Aytu BioPharma announced its fiscal 2026 first quarter operational and financial results, confirming the EXXUA launch remains on track for the fourth calendar quarter of 2025.

Summary

• Net revenue for the first quarter of fiscal 2026 was $13.9 million, compared to $16.6 million in Q1 fiscal 2025; excluding a one-time $3.3 million rebate in Q1 fiscal 2025, net revenue increased 5%.
• Net income rose to $2.0 million, or $0.21 per basic share, from $1.5 million in Q1 fiscal 2025.
• Adjusted EBITDA was $(0.6) million, down from $1.9 million in Q1 fiscal 2025, primarily due to investments for the EXXUA launch.
• Cash and cash equivalents stood at $32.6 million as of September 30, 2025, an increase from $31.0 million at June 30, 2025.
• The commercial launch of EXXUA, a novel treatment for Major Depressive Disorder (MDD), remains on track for the fourth calendar quarter of 2025, with initial shipments expected in December 2025.
• The method of use patent for EXXUA was extended through September 2, 2030, further expanding intellectual property protection.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While adjusted EBITDA is negative due to launch investments, the company reported increased net income, positive cash flow, and strong progress on the EXXUA launch, which is a significant future growth driver with extended patent protection. The underlying ADHD business also showed growth when adjusted for a prior-year anomaly.

Positives

• Net income increased to $2.0 million in Q1 fiscal 2026 from $1.5 million in Q1 fiscal 2025.
• Excluding a one-time rebate benefit, net revenue increased 5% compared to the year-ago quarter.
• ADHD Portfolio net revenue, excluding the rebate, increased 10% compared to the year-ago quarter, demonstrating stability and sequential growth.
• Cash and cash equivalents increased to $32.6 million at September 30, 2025, from $31.0 million at June 30, 2025.
• The commercial launch of EXXUA for MDD remains on track for the fourth calendar quarter of 2025, with significant progress in manufacturing, sales force training, and market preparation.
• The method of use patent for EXXUA was extended through September 2, 2030, enhancing intellectual property protection and market exclusivity.

Negatives

• Total net revenue decreased to $13.9 million in Q1 fiscal 2026 from $16.6 million in Q1 fiscal 2025 (though this was largely due to a one-time rebate in the prior year).
• Adjusted EBITDA was $(0.6) million, a decrease from $1.9 million in Q1 fiscal 2025, attributed to EXXUA launch investments.
• Pediatric Portfolio net revenue decreased to $0.7 million from $1.3 million in Q1 fiscal 2025, primarily due to manufacturing delays and a deemphasis in marketing.

Risks

• Risks associated with the company's overall financial and operational performance.
• Potential adverse changes to the company's financial position or its business, results of operations, strategy, and plans.
• Changes in capital markets and the ability of the company to finance operations in the manner expected.
• Risks relating to gaining market acceptance of its products.
• Risks related to its partners performing their required activities.
• Risks concerning its anticipated future cash position.
• Regulatory and compliance challenges.
• Future events under current and potential future collaborations.

Future Outlook

The company remains on track to launch EXXUA in the fourth calendar quarter of 2025, positioning it as a major growth catalyst in the over $22 billion United States prescription major depressive disorder market. Management anticipates continued focus on the EXXUA launch while maintaining stability in the ADHD Portfolio, with ongoing efforts to expand intellectual property for EXXUA through life cycle management approaches.

Management Comments

• "The Aytu team is fully executing on the tremendous opportunity ahead of us to become one of the leaders in addressing complex central nervous system diseases, with a focus on the upcoming launch of EXXUA for major depressive disorder, as well as our ongoing ADHD Portfolio."
• "The EXXUA launch remains on track to occur by the end of the fourth quarter of calendar 2025, with significant advancements being made to ensure success, including KOL engagement, sales force training, product positioning and pricing, payor assessments and integration with our proprietary Aytu RxConnect patient access platform."
• "While much of our commercial efforts are focused on the launch of EXXUA, it is gratifying to see that our ADHD Portfolio remains stable. In fact, excluding the one-time benefit from the rebate received in the year ago quarter, ADHD Portfolio net revenue would have increased 10% compared to the year ago period, and was also up on a sequential basis as well."
• "This stability reinforces our long-term belief on the added stickiness and positive economic benefits that are inherent in our Aytu RxConnect platform through which approximately 85% of our branded ADHD prescriptions are dispensed."
• "The coming months are going to be exciting for Aytu. We are laser focused on a successful commercial launch of EXXUA as we focus on positively impacting the lives of the estimated 21 million Americans affected by MDD."

Industry Context

Aytu BioPharma is entering the substantial over $22 billion United States prescription major depressive disorder (MDD) market with EXXUA, a novel first-in-class selective serotonin 5HT1a receptor agonist. This positions the company to potentially capture a significant share in a market with high unmet needs, differentiating itself with a new chemical entity. The continued stability and growth of its ADHD portfolio, supported by its Aytu RxConnect platform, also reflects ongoing demand in the attention deficit hyperactivity disorder treatment sector.

Comparison to Industry Standards

• EXXUA is highlighted as a 'first-in-class' selective serotonin 5HT1a receptor agonist, distinguishing it from existing MDD treatments which often target different mechanisms (e.g., SSRIs, SNRIs). This unique mechanism could offer a differentiated profile in the competitive MDD market, which includes established players like Pfizer (Zoloft), Eli Lilly (Prozac, Cymbalta), and Takeda (Trintellix).
• The MDD market is valued at over $22 billion in the U.S., indicating a significant opportunity for a new entrant like EXXUA, especially given the estimated 21 million Americans affected by MDD.
• The company's ADHD portfolio, showing a 10% net revenue increase (excluding a one-time rebate), suggests a solid performance in a market with consistent demand, comparable to other specialty pharmaceutical companies with established product lines.

Stakeholder Impact

• Shareholders: Potential for future revenue growth and increased shareholder value through the successful launch of EXXUA and continued stability of the ADHD portfolio, offset by current investment-related expenses.
• Patients: Introduction of a novel, first-in-class treatment (EXXUA) for Major Depressive Disorder, offering a new therapeutic option for adults.
• Employees: Expansion of the sales force and training for the EXXUA launch, indicating potential for job growth and strategic focus.
• Suppliers: Resolution of manufacturing delays impacting the Pediatric Portfolio is ongoing, which could affect supplier relationships and future product availability.

Next Steps

• Finalize product manufacturing, labeling, serialization, and shipment of EXXUA to the third-party logistics provider, with initial shipments in December 2025.
• Complete sales force training for EXXUA in the coming weeks.
• Conduct the EXXUA launch meeting in mid-January 2026.
• Continue discussions with commercial and government payors for EXXUA.
• Finalize EXXUA integration into the Aytu RxConnect patient access platform.
• Engage in discussions to expand upon existing intellectual property for EXXUA through various potential life cycle management approaches.

Key Dates

Recommendation

Aytu BioPharma presents a mixed financial picture for Q1 FY26, with a decline in reported net revenue but an increase when adjusted for a prior-year rebate, and a positive net income. The negative adjusted EBITDA is a direct result of strategic investments in the EXXUA launch, a critical growth driver. The successful progress of the EXXUA launch, coupled with its patent extension through 2030, provides a strong long-term growth catalyst in a significant market. However, the immediate financial impact of these investments and the decline in the Pediatric Portfolio warrant a cautious approach. For a seasoned investor, the current period represents a transition with significant upfront costs for future revenue. A 'hold' recommendation allows investors to monitor the initial uptake and commercial success of EXXUA while acknowledging the company's strategic positioning for long-term value creation, without committing to further capital until launch metrics become clearer.

Keywords

Aytu BioPharma, AYTU, EXXUA, Major Depressive Disorder, MDD, Gepirone, ADHD, Pharmaceutical, Biopharma, Q1 Fiscal 2026, Earnings, Financial Results, Drug Launch, CNS Diseases